These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


414 related items for PubMed ID: 23838141

  • 1. The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer.
    Wang P, Piao Y, Zhang X, Li W, Hao X.
    Cancer Biomark; 2013; 13(2):123-30. PubMed ID: 23838141
    [Abstract] [Full Text] [Related]

  • 2. [Value of tumor markers in the cerebrospinal fluid in the diagnosis of meningeal carcinomatosis].
    Shi Q, Pu CQ, Wu WP, Huang XS, Yu SY, Tian CL, Huang DH, Zhang JT.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1192-4. PubMed ID: 20501426
    [Abstract] [Full Text] [Related]

  • 3. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [Abstract] [Full Text] [Related]

  • 4. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA, Liu X, Tian XD, Wang W, Liang CY, Zhang T, Guo JT, Peng YH, Zhou NK.
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [Abstract] [Full Text] [Related]

  • 5. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B, He YJ, Tian YX, Yang RN, Zhu YR, Qiu H.
    Asian Pac J Cancer Prev; 2014 Oct; 15(22):9611-4. PubMed ID: 25520076
    [Abstract] [Full Text] [Related]

  • 6. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Oct; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
    Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y.
    Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
    [Abstract] [Full Text] [Related]

  • 8. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S, Shen L, Qian N, Chen K.
    Cancer Biomark; 2013 Apr; 10(3-4):155-62. PubMed ID: 22674301
    [Abstract] [Full Text] [Related]

  • 9. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF, Wang M, Xu JL.
    Life Sci; 2018 Feb 01; 194():1-6. PubMed ID: 29247745
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W, Hoppe M, Muley T, Drings P.
    Anticancer Res; 1997 Feb 01; 17(4B):2875-8. PubMed ID: 9329552
    [Abstract] [Full Text] [Related]

  • 11. [Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].
    Lin Y, Li H, Huang M, Yin Z, Wu J.
    Zhongguo Fei Ai Za Zhi; 2020 Jun 20; 23(6):516-525. PubMed ID: 32517459
    [Abstract] [Full Text] [Related]

  • 12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Jun 20; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 13. [The value of serum tumor marker in the diagnosis of lung cancer].
    Shi GL, Hu XL, Yue SD, Song CX.
    Zhonghua Zhong Liu Za Zhi; 2005 May 20; 27(5):299-301. PubMed ID: 15996327
    [Abstract] [Full Text] [Related]

  • 14. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 May 20; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 15. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD, Beinert T, Fürst H, Fink U.
    Lung Cancer; 1999 Dec 20; 26(3):149-55. PubMed ID: 10598925
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
    Lee JH, Chang JH.
    Chest; 2005 Oct 20; 128(4):2298-303. PubMed ID: 16236887
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer.
    Li J, Chen P, Mao CM, Tang XP, Zhu LR.
    Asia Pac J Clin Oncol; 2014 Jun 20; 10(2):141-8. PubMed ID: 23551358
    [Abstract] [Full Text] [Related]

  • 18. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
    Zhang L, Liu D, Li L, Pu D, Zhou P, Jing Y, Yu H, Wang Y, Zhu Y, He Y, Li Y, Zhao S, Qiu Z, Li W.
    BMC Cancer; 2017 Feb 02; 17(1):96. PubMed ID: 28152979
    [Abstract] [Full Text] [Related]

  • 19. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
    Lazarev SM, Massard Zh, Reshetov AV, Nikolaev GV, Volgin GN, Osipov EV, Lomteva EIu, Nokhrin AV, Kakysheva OE.
    Vestn Khir Im I I Grek; 2010 Feb 02; 169(1):39-43. PubMed ID: 20387605
    [Abstract] [Full Text] [Related]

  • 20. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, Guerrero JM.
    Clin Lab; 2011 Feb 02; 57(11-12):1011-4. PubMed ID: 22239035
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.